Hospital
Affinity Hospital LLC
Affinity Hospital LLC was paid $899K by Medicaid between Jan 2018 and Nov 2024, across 60 billing codes. Its largest line is 99284, emergency room visit (serious) — 48% of everything it billed.
33Billing provider infoAFFINITY HOSPITAL LLC
BIRMINGHAM, AL 35243
BIRMINGHAM, AL 35243
33aNPI1023061405assigned 05/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$899K
24GClaims50,229
24DCodes billed60
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#49 of 77
Median peer was paid$1.13M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,104 | $129K | |
| 2019 | 9,019 | $116K | |
| 2020 | 5,688 | $66K | |
| 2021 | 6,438 | $97K | |
| 2022 | 6,921 | $124K | |
| 2023 | 6,996 | $191K | |
| 2024incomplete | 6,063 | $176K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 48% | 7,061 | 6,252 | $428K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 4,766 | 4,308 | $178K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 9.5% | 11,323 | 9,784 | $85K |
| 80053 | Comprehensive metabolic panel | 9.2% | 9,032 | 7,662 | $82K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.4% | 1,061 | 1,016 | $31K |
| 87070 | 2.6% | 2,037 | 1,978 | $23K | |
| 86780 | 1.7% | 855 | 818 | $15K | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.3% | 46 | 43 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 758 | 648 | $8K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 159 | 152 | $3K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 167 | 151 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 229 | 220 | $3K |
48 more codes
| 81001 | <1% | 758 | $3K | |
| 86762 | <1% | 114 | $2K | |
| 86592 | <1% | 376 | $2K | |
| 80061 | Lipid panel | <1% | 144 | $1K |
| 87340 | <1% | 113 | $1K | |
| 86850 | <1% | 247 | $1K | |
| 84439 | <1% | 213 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 28 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 44 | $1K |
| 85027 | <1% | 391 | $1K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 95 | $916.26 |
| 71045 | Radiologic examination, chest; single view | <1% | 209 | $898.11 |
| 0002A | <1% | 28 | $880.00 | |
| 87081 | <1% | 77 | $769.74 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 17 | $759.50 |
| 85014 | <1% | 265 | $746.06 | |
| 80164 | <1% | 69 | $706.70 | |
| 86787 | <1% | 40 | $698.36 | |
| 87428 | <1% | 15 | $679.00 | |
| 82105 | <1% | 29 | $586.36 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 35 | $514.10 |
| 82947 | <1% | 126 | $453.00 | |
| 86900 | <1% | 143 | $417.67 | |
| 86901 | <1% | 143 | $402.39 | |
| 0001A | <1% | 12 | $360.00 | |
| 80305 | <1% | 39 | $342.93 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 48 | $254.52 |
| 84484 | <1% | 47 | $253.78 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 13 | $234.24 |
| 87430 | <1% | 21 | $224.56 | |
| 82607 | <1% | 14 | $219.90 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 13 | $192.50 |
| 83020 | <1% | 13 | $189.90 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 46 | $184.64 |
| 81025 | <1% | 46 | $175.32 | |
| 83690 | <1% | 43 | $171.65 | |
| 83655 | <1% | 15 | $168.20 | |
| 81003 | <1% | 82 | $131.60 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $107.76 |
| 82247 | <1% | 17 | $102.40 | |
| 85018 | <1% | 26 | $86.75 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 26 | $65.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 71 | $44.45 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,072 | $37.03 |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,506 | $20.16 |
| G0475 | Hiv antigen/antibody, combination assay, screening | 0% | 674 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 112 | $0.00 |
| 91300 | 0% | 46 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Northwest Hospital LLC | Tucson, AZ | $47.81M |
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.